Skip to main content
Back
MTHRF logo

M3, Inc.

Data quality: 100%
MTHRF
OTC Healthcare Medical - Healthcare Information Services
$11.00
$0.00 (0.00%)
Mkt Cap: 7.45B
Also listed as MTHRY OTC
Day Range
$11.00 $11.00
52-Week Range
$9.45 $15.25
Volume
300
50D / 200D Avg
$12.02 / $13.38
Prev Close
$11.00

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 0.2 0.4
P/B 0.0 2.9
ROE % 11.1 3.7
Net Margin % 14.2 3.9
Rev Growth 5Y % 13.9 10.0
D/E 0.1 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $121.57
$118.57 – $127.11
 520 B 1
FY2029 $107.85
$105.19 – $112.77
 470 B 1
FY2028 $93.04
$90.74 – $97.28
 430 B 1

Key Takeaways

Revenue grew 13.91% annually over 5 years — strong growth
Earnings declined -10.57% over the past year
ROE of 11.09% — decent returns on equity
Debt/Equity of 0.06 — conservative balance sheet
Generating 42.75B in free cash flow
P/E of 0.18 — trading at a low valuation

Growth

Revenue Growth (5Y)
13.91%
Revenue (1Y)19.26%
Earnings (1Y)-10.57%
FCF Growth (3Y)-7.10%

Quality

Return on Equity
11.09%
ROIC11.72%
Net Margin14.21%
Op. Margin22.10%

Safety

Debt / Equity
0.06
Current Ratio2.96
Interest Coverage87.83

Valuation

P/E Ratio
0.18
P/B Ratio0.02
EV/EBITDA-1.64
Dividend Yield0.01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 19.26% Revenue Growth (3Y) 11.10%
Earnings Growth (1Y) -10.57% Earnings Growth (3Y) -9.13%
Revenue Growth (5Y) 13.91% Earnings Growth (5Y) 1.71%
Profitability
Revenue (TTM) 284.90B Net Income (TTM) 40.48B
ROE 11.09% ROA 6.96%
Gross Margin 54.18% Operating Margin 22.10%
Net Margin 14.21% Free Cash Flow (TTM) 42.75B
ROIC 11.72% FCF Growth (3Y) -7.10%
Safety
Debt / Equity 0.06 Current Ratio 2.96
Interest Coverage 87.83 Dividend Yield 0.01%
Valuation
P/E Ratio 0.18 P/B Ratio 0.02
P/S Ratio 0.03 PEG Ratio -2.24
EV/EBITDA -1.64 Dividend Yield 0.01%
Market Cap 7.45B Enterprise Value -103.06B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 284.90B 238.88B 230.82B 208.16B 169.20B
Net Income 40.48B 45.27B 49.03B 63.85B 37.82B
EPS (Diluted) 59.60 66.63 72.17 93.98 55.68
Gross Profit 154.36B 140.53B 135.19B 123.27B 103.40B
Operating Income 62.97B 64.38B 71.98B 95.14B 58.36B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 581.74B 490.78B 400.65B 345.98B 273.12B
Total Liabilities 168.94B 124.08B 91.13B 82.03B 65.86B
Shareholders' Equity 378.44B 351.92B 302.63B 257.84B 199.81B
Total Debt 24.42B 18.51B 10.38B 8.30B 5.42B
Cash & Equivalents 134.93B 149.66B 118.32B 104.25B 89.14B
Current Assets 243.43B 240.74B 203.47B 198.87B 164.11B
Current Liabilities 82.11B 67.17B 59.58B 57.22B 50.31B

Strategy Scores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#351 of 1024
52
Custom Deep Value Investing (Seth Klarman)
#396 of 820
43
Growth Price/Sales Ratio Focus (Ken Fisher)
#485 of 616
17
Value Defensive Investing (Benjamin Graham)
#577 of 708
11

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026